Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases

Regulatory T cells (Treg) are crucial for the maintenance of peripheral tolerance and for the control of ongoing inflammation and autoimmunity. The cytokine interleukin-2 (IL-2) is essentially required for the growth and survival of Treg in the peripheral lymphatic tissues and thus plays a vital role in the biology of Treg. Most autoimmune and rheumatic diseases exhibit disturbances in Treg biology either at a numerical or functional level resulting in an imbalance between protective and pathogenic immune cells. In addition, in some autoimmune diseases, a relative deficiency of IL-2 develops during disease pathogenesis leading to a disturbance of Treg homeostasis, which further amplifies the vicious cycle of tolerance breach and chronic inflammation. Low-dose IL-2 therapy aims either to compensate for this IL-2 deficiency to restore a physiological state or to strengthen the Treg population in order to be more effective in counter-regulating inflammation while avoiding global immunosuppression. Here we highlight key findings and summarize recent advances in the clinical translation of low-dose IL-2 therapy for the treatment of autoimmune and rheumatic diseases.

Automated summary

Regulatory T cells (Treg) are crucial for maintaining peripheral tolerance and controlling inflammation and autoimmunity, with the cytokine interleukin-2 (IL-2) playing a key role in their growth and survival. Many autoimmune and rheumatic diseases show disruptions in Treg biology, leading to an imbalance between protective and pathogenic immune cells. Low-dose IL-2 therapy aims to restore physiological balance by compensating for IL-2 deficiency and strengthening the Treg population to counteract inflammation effectively.